플레이크형 마이크로캐리어 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Flake Microcarrier Market

The future of the global flake microcarrier market looks promising with opportunities in the cell therapy and vaccine production markets. The global flake microcarrier market is expected to reach an estimated $136.8 million by 2035 from $78.5 million in 2027 with a CAGR of 7.5% from 2027 to 2035. The major drivers for this market are the increasing demand for cell based therapies, the rising use in vaccine production, and the growing adoption in biopharmaceutical manufacturing.

• Lucintel forecasts that, within the type category, 500g is expected to witness the highest growth over the forecast period due to ideal batch size for 500g units.
• Within the application category, vaccine production is expected to witness higher growth over the forecast period due to increased need for vaccine and cell culture production.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased demand for biopharmaceuticals.

Emerging Trends in Flake Microcarrier Market

Leading microcarrier manufacturers have targeted cell therapy, vaccines, and other similar fields; this is reflected in recent product launches and investments. Clients will emphasize return on investment (ROI) in the 2025-2027 timeframe by considering closed processing, coating consistency, and regulatory status of products. We, at Lucintel, expect continued investment by biopharmaceutical companies for development and commercialization of next-generation biologics and cell therapy products. This investment will fuel the demand for flexible and integrated bioprocessing platforms.

We expect multiple shifts in the industry between 2025 and 2026.

• Sustainability: Decreasing the use of harsh chemicals and solvents, and reducing process waste will drive purchasing decisions. Expectations for microcarriers will continue to decrease, to the point that they may not be recoverable.
• Automation: Control and automation of sampling and other processes will drive the shift away from manual processes in bioreactor engineering.
• Functional Products: The adoption of xeno-free and other animal component-free systems will continue. Other industry shifts will include the use of systems and components tailored for the attachment and release of specified cells and the use of more complex chemistries for microcarriers. These shifts will also allow customers to charge a premium.
• Digitalization and Automation in Cell Therapy Development: Continued investment by biopharmaceutical companies will promote the use of design-of-experiment strategies and other digital and automated processes to develop and gain regulatory approval for cell therapy products. Digital information will replace paperwork, creating an increased demand for integrated and interoperable systems.
• Biomanufacturing Supply Chain Diversification and Local Sourcing: Diversification of North American, European, and Asian biomanufacturing supply chains is prompting local sourcing of critical supplies. Starting in 2025, contracts will more routinely contain duo /source provisions. Increasing the number of locations where supplies are produced would reduce the company's exposure to disruptions and enhance the company's confidence in the delivery of supplies as the company's clinical programs grow and expand.

Flake microcarriers would primarily be used to support the production of cells at the commercial level. Depending on the microcarrier's physical characteristics, its recovery yield and the consistency of the coating, its automation and combination with other processes would determine its attractiveness to customers. The medical needs of the population would drive the continued investment in advanced therapies.

Recent Developments in the Flake Microcarrier Market

Through 2027, the market for flake microcarriers is anticipated to experience strong growth, as customers in the cell and gene therapy markets require greater surface area microcarriers with less agitation. Lucintel expects the market will continue to grow based on increased automation of processes, more stringent documentation requirements, and further sub-segmentation of the market. The validation of the comparability of flake formats with respect to recovery and other regulatory requirements will also impact the market.

• Additional Capacity: In April 2025, Samsung Biologics announced the completion of its 180,000 liter Biomanufacturing plant, increasing its capacity by 23% to 784,000 liters. Given the growing demand for larger biomanufacturing plants, suppliers of scalable microcarriers are expected to bring high throughput, and validated flake formats to the market.
• Cell Therapy Manufacturing: The $1.2 Billion Fujifilm investment in May 2025, to expand the Holly Springs site for cell therapy manufacturing created a large adherent cell culture facility. Flake formats that support cell adhesion are expected to gain market traction.
• Automation: In January 2025, Thermo Fisher (as Gibco) launched an automation platform for advanced therapies. Given automation trends in cell culture, flake microcarriers formats that enable real time monitoring of the cell culture process are expected to gain traction.
• Strategic Alliances: 2025 saw a continuation of partnerships between single use and downstream suppliers. These alliances will help gain comparability of flake microcarriers, particularly as customers expect integrated process and supplier solutions.
• Regulatory Momentum: The US FDA greenlighted 10 novel cell and gene therapies by the end of 2024, setting a trend for similar biologics and creating a race against time to develop these therapies. Regulatory momentum coupled with advances in cellular processing and manufacturing has created a sense of urgency among industry stakeholders to standardize the supply of raw materials. Traceability and comparability of raw materials, and the absence of animal components in raw materials will help raw material suppliers win new business. These factors will propel suppliers to gain a competitive edge in the cell and gene therapy market.

Recent industry trends favor the use of microcarriers for cell cultures. There is a move away from laboratory experimentations to using microcarriers for processes at commercial scales. Continuous improvements in the design and engineering of microcarriers, and raw material suppliers' ability to stably and reliably produce microcarriers of specified geometry will likely enhance the commercial adoption of microcarriers for cell cultures.

Strategic Growth Opportunities in the Flake Microcarrier Market

Between 2024 and 2026, industry focus will be shifting from 2D cell culture to forms of cell expansion that are at a greater scale. This will occur in the context of the advancement of new therapeutic fields, such as organoid research and cell culture, as well as vaccine development and production. Companies that manufacture Flake microcarriers are well positioned to address this shifting market need through the development and introduction of a portfolio of products designed to address specific applications. Sustained investment in the bioprocessing field and increasing emphasis on process readiness and reproducibility in the cell culture industry are reflected in Lucintel's recent market observations.

• Cell and Gene Therapy: Flake microcarriers enable cell expansion of adherent cell types in bioprocessing. Sustained investment in bioprocessing, as indicated by Sartorius's 2024 revenues, ensures that the market is receptive to microcarriers. It is anticipated that new, higher-yield microcarriers will be adopted to meet the needs of the market.
• Regenerative Medicine: A wide range of Flake-based microcarriers are available for the culture and expansion of mesenchymal stem cells and other adherent cell types. This is particularly relevant to the field of tissue engineering.
• Customized Coating Solutions: Suppliers of cell culture microcarriers can charge higher prices by selling customized coatings tailored for a particular cell type, growth media, and bioreactor conditions. Traditionally, suppliers sell microcarriers in the form of polymer flakes and charge low prices for the flakes. Demand for specialty life science reagents is growing. Corning is a good example. In March 2025, Corning announced that its sales for the year surpassed $12 billion. Suppliers of microcarriers should also focus on developing different formats of their products.
• Expanding Operations in The Asia-Pacific Region is Also A Good Strategy: Locating manufacturing facilities in the Asia-Pacific region will enable suppliers to produce their products in the region, utilize local labor, and decrease their dependence on imports from other countries. Investment in biomanufacturing by countries in the Asia-Pacific region will provide suppliers an opportunity to sell their products to small, growing biomanufacturing companies.
• Developing Sustainable Single-use Products is A Good Strategy: The EU's policy to reduce the use of certain petroleum-based products and its directive to make packaging products sustainable by 2030 will encourage suppliers to develop sustainable products. Other suppliers should also focus on developing products that will help their customers reduce their carbon footprint. Customers will favor suppliers of single-use bioreactors with sustainable products.

Flake Microcarrier Market Drivers and Challenges

Technological advances, increasing biopharmaceutical investment and favorable economics in manufacturing facilitates growing demands for the regulation of biopharmaceuticals. All of these amplify the need for reliable systems for large-scale expansion of cellular raw materials. Lucintel believes that these trends will help shape the microcarrier market.

The factors responsible for driving this market include:

• Customer Requests: The increasing demand for adherent-cell expansion for the manufacture of cell and gene therapies, biologics and other vacation products has created a requests for reliable systems. In 2025, sponsors and contract development and manufacturing organizations (CDMOs) targeted increased productivity and reduced manual interventions in cell-culture processes. Flake microcarriers have potential to achieve these objectives. Additionally, use of flake microcarriers for seed-train expansion may result in smaller process facilities. It is anticipated that in the next 3-5 years, with continued growth in the commercialization of cell-based therapies and biologics, supplier focus will be on development of systems and microcarriers for expansions of insect, stem and other cell-types of interest.
• Improving Technology: Flake microcarriers continued to evolve in 2025. Concurrently, cell culture practices and media became better-suited to low-shear environments and imaging-compatible formats to enable culture of sensitive cells, including 3D cell cultures. Many of these advances allowed cells to retain their phenotype and easier harvesting. Furthermore, the integration of automation with bioreactors, and process analytical technologies, increased process control during cell culture. It is expected that in the next 3 to 5 years, continuous improvements in flake microcarriers and process controls would enable microcarrier cell culturing for cell therapeutics.
• Regulatory Landscape: During the same time period (2025), forward-thinking regulators supported the use of closing process and supply chains, as well as characterization of starting cellular materials, within the framework of advanced and adaptable manufacturing for biologics and therapeutics. Standardized, flake microcarriers, in combination with a defined and documented process, support closure of the manufacturing system. Composition and/or formulation of flake microcarriers, and validation of sterilization, supported quality assurance. Supported by regulatory guidance and increased process control, microcarriers are anticipated to play an increased role in advanced therapeutics and biologics in the next 3 to 5 years.
• Sustainability: Limits on natural resources and greater awareness of the environmental impact of bioprocessing have resulted in increasing emphasis on sustainability. Consequently, companies are increasing focus on improving productivity of their culture systems, reducing their reliance on single-use systems, reducing facility footprint, and optimizing the use of other process resources. Use of microcarriers in bioprocessing has the potential to improve these aspects, in addition to reducing process volumes and time. Development of processes to improve the sustainability of microcarriers, and their use in bioprocessing will gain importance in the next 3-5 years.
• Manufacturing Efficiency: The use of automation and other process improvements to increase density in cell cultures has driven the bioprocessing industry to reduce the size of seed trains and increase operator intervention to control cell cultures. Use of microcarriers in bioprocessing achieves these goals in addition to other benefits. Improvements in microbial genome engineering and other process automation technologies will improve the use of microcarriers in cell cultures, particularly in large scale operations. This will increase the demand for microcarriers from contract manufacturing and development organizations (CDMOs) in the next 3-5 years.

The Challenges facing for this Market include:

• Higher Costs for Development and Validation: Flake microcarriers require tests for attachment and growth as well as shear and sterilization. Additionally, extractables testing and compatibility with various cell types are required. In 2025, clients performed application qualifications before replacing established culture systems, thereby extending the average purchase cycle. Smaller companies in the biopharmaceutical industry, especially those without dedicated process development resources and sufficient financial resources, may find it difficult to perform the qualifications. Finally, cell type may affect the requirements for qualification.
• Product Complexity and Process Intricacy: Flake microcarriers may result in issues including cell aggregation, mixed cell populations, protein and cell line foams, and sample contaminations. In 2025, process developers were able to optimize design variables including agitation and feeding for specific cell lines. Attachment and viability of a microcarrier for a given cell line may vary. This increases the complexity of process development and may complicate technology transfer. In the next several years it is expected that microcarriers will be developed that have improved properties for cell line recovery and reduced process complexity.
• Supply Chain and Regulatory Risk: Reliance on specific polymers and coatings, sterilization and test services, and qualified components exposes the market to supply disruptions and price increases. Bioprocessing companies encountered challenges in 2025 due to the unavailability of critical materials. Dual sourcing and inventory planning were the only strategies to alleviate the challenges. Effective implementation of these strategies reduced the lead time for clinical trials. Raw material changes by a supplier may require a bioprocessing company to repeat its validation process. However, suppliers that have manufacturing sites in different regions, ensure raw material traceability, and effectively implement change control can assist in continuous and uninterrupted production for a bioprocessing company.

The increasing adoption of large-scale cell culture, advancements in cell culture processes and the growing application of cell therapies and biologics will propel the microcarriers market. The microcarriers market is also impacted by the regulatory and sustainability trends. Challenges in technology implementation and supply chain variability will impact the market. Continuous improvement in technology will aid in achieving process consistency, broader cell type coverage and larger scale cell culture. Bioprocessing companies should implement track and field strategies. Bioprocessing companies should partner with suppliers that have similar focus, strategies and implemented improvements.

List of Flake Microcarrier Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies flake microcarrier market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the flake microcarrier market companies profiled in this report include-

• Eppendorf
• SP Bel-Art
• LePure Biotech
• Shanghai Duoning Biotechnology
• Wuhan CEKG Tech

Flake Microcarrier Market by Segment

The study includes a forecast for the global flake microcarrier market by type, application, and region.

Flake Microcarrier Market by Type [Value ($M) from 2019 to 2035]:

• 50g
• 250g
• 500g
• 1kg

Flake Microcarrier Market by Application [Value ($M) from 2019 to 2035]:

• Cell Therapy
• Vaccine Production
• Others

Flake Microcarrier Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Flake Microcarrier Market

According to Lucintel, one of the key drivers propelling the flake microcarrier market is the increasing emphasis on the scalable manufacturing of cell cultures and progressive regulation in the field of advanced cellular therapies. Between 2025 and 2027, predictably, the bioprocessing industry will deploy greater automation and single-use systems. Tightening requirements in the cell-and-gene-therapy sector are expected to stimulate the adoption of high-surface-area culture technologies.

• United States: In the United States, Thermo Fisher Scientific's $2 billion investment in U.S. bioproduction and bioprocessing (announced in January 2025) will, among other things, sponsor the expansion of single-use technologies and cellular production systems. It is anticipated that this will foster the large-scale, commercial cultivation of cellular therapies and other products and boost the utilization of flake microcarriers in cellular biomanufacturing.
• China: Growth in Cell Therapy: China's National Medical Products Administration released an updated set of guidelines in 2025 on the evaluation of human cell-based therapies. WuXi AppTec also expanded its cell and gene therapy services. Standardized cell-based therapy manufacturing processes, clarification of cell-based therapy guidelines, and expanding manufacturing capacity will allow cell therapy to be widely available.
• Germany: Production Capabilities: The German branch of Sartorius reported 2024 revenue of approximately €3.4 billion and continued its investments on large-scale production equipment in 2025. With additional production capacity in Germany, Sartorius and other large suppliers can produce complete single-use systems, including microcarriers, for the European biologics market.
• India: Government Support: India's BioE3 policy began enforcement in 2025, with an aim to create 20 biomanufacturing facilities and address biomanufacturing and precision medicine. Funding and policy support strengthen the case for local investment in cell culture and other related technologies.
• Japan: Investments: In 2025, Fujifilm Diosynth Biotechnologies began the construction of its cell culture-based manufacturing facility in Thousand Oaks, expected to be completed in 2026. Fujifilm's investments enhance the microcarrier and large-scale cell-based manufacturing capacity in Japan.

Features of the Global Flake Microcarrier Market

• Market Size Estimates: flake microcarrier market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: flake microcarrier market size by type, application, and region in terms of value ($B).
• Regional Analysis: flake microcarrier market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the flake microcarrier market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the flake microcarrier market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the flake microcarrier market by type (50g, 250g, 500g, and 1kg), application (cell therapy, vaccine production, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Flake Microcarrier Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 50g : Trends and Forecast 2019 to 2035
• 4.4 250g : Trends and Forecast 2019 to 2035
• 4.5 500g : Trends and Forecast 2019 to 2035
• 4.6 1kg : Trends and Forecast 2019 to 2035

5. Global Flake Microcarrier Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Cell Therapy : Trends and Forecast 2019 to 2035
• 5.4 Vaccine Production : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Flake Microcarrier Market by Region

7. North American Flake Microcarrier Market

• 7.1 Overview
• 7.2 North American Flake Microcarrier Market by Type
• 7.3 North American Flake Microcarrier Market by Application
• 7.4 The United States Flake Microcarrier Market
• 7.5 Canadian Flake Microcarrier Market
• 7.6 Mexican Flake Microcarrier Market

8. European Flake Microcarrier Market

• 8.1 Overview
• 8.2 European Flake Microcarrier Market by Type
• 8.3 European Flake Microcarrier Market by Application
• 8.4 German Flake Microcarrier Market
• 8.5 French Flake Microcarrier Market
• 8.6 Italian Flake Microcarrier Market
• 8.7 Spanish Flake Microcarrier Market
• 8.8 The United Kingdom Flake Microcarrier Market

9. APAC Flake Microcarrier Market

• 9.1 Overview
• 9.2 APAC Flake Microcarrier Market by Type
• 9.3 APAC Flake Microcarrier Market by Application
• 9.4 Chinese Flake Microcarrier Market
• 9.5 Indian Flake Microcarrier Market
• 9.6 Japanese Flake Microcarrier Market
• 9.7 South Korean Flake Microcarrier Market
• 9.8 Indonesian Flake Microcarrier Market

10. ROW Flake Microcarrier Market

• 10.1 Overview
• 10.2 ROW Flake Microcarrier Market by Type
• 10.3 ROW Flake Microcarrier Market by Application
• 10.4 Middle Eastern Flake Microcarrier Market
• 10.5 South American Flake Microcarrier Market
• 10.6 African Flake Microcarrier Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Flake Microcarrier Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Eppendorf
  • Company Overview
  • Flake Microcarrier Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 SP Bel-Art
  • Company Overview
  • Flake Microcarrier Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 LePure Biotech
  • Company Overview
  • Flake Microcarrier Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Shanghai Duoning Biotechnology
  • Company Overview
  • Flake Microcarrier Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Wuhan CEKG Tech
  • Company Overview
  • Flake Microcarrier Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us